Restricted accessResearch articleFirst published online 2019-12-12
APOE ɛ 4/ ɛ 4 Is Associated with Aberrant Motor Behavior Through Both Lewy Body and Cerebral Amyloid Angiopathy Pathology in High Alzheimer’s Disease Pathological Load
Aberrant motor behavior (AMB) is a neuropsychiatric symptom (NPS) prevalent in Alzheimer’s disease (AD), known to cause great distress to both patients and caregivers. Apolipoprotein E4 (APOE4) is the most important genetic predictor of AD, and it has been associated with high NPS prevalence.
Objective:
To investigate the neuropathological substrates and risk factors associated with AMB in AD patients.
Methods:
Cases with Braak stage I-II and CERAD 0-1 were classified as Low AD (LAD), while Braak stage III-IV and CERAD 2 were grouped as Intermediate AD (IAD). Cases with Braak stage V-VI and CERAD 3 were classified as High AD (HAD) in accordance with NIA-Reagan criteria. All cases were stratified by APOE genotype, yielding No ɛ4 & ɛ4 and ɛ4/ɛ4 groups depending on ɛ4 copy number within APOE. Presence of AMB was assessed using NPI-Q.
Results and Conclusion:
AMB increased in parallel with CERAD and Braak & Braak scores. Hypercholesterolemia, but no other cardiovascular risk factors, was associated with AMB in HAD. AMB prevalence in HAD was significantly increased in the presence of two APOEɛ4 alleles as compared to No ɛ4 & ɛ4. The relationship between homozygous APOE4 and AMB was strongly associated with the presence of both Lewy bodies and cerebral amyloid angiopathy pathologies in both sexes.
SteinbergM, SheppardJM, TschanzJT, NortonMC, SteffensDC, BreitnerJCS, LyketsosCG (2003) The incidence of mental and behavioural disturbances in dementia: The Cache County Study. J Neuropsychiatry Clin Neurosci15, 340–345.
5.
SiafarikasN, SelbaekG, FladbyT, Saltyte BenthJ, AuningE, AarslandD (2018) Frequency and subgroups of neuropsychiatric symptoms in mild cognitive impairment and different stages of dementia in Alzheimer’s disease. Int Psychogeriatr30, 103–113.
6.
Fernandez-MartinezM, CastroJ, MolanoA, ZarranzJJ, RodrigoRM, OrtegaR (2008) Prevalence of neuropsychiatric symptoms in Alzheimer's disease and vascular dementia. Curr Alzheimer Res5, 61–69.
7.
IkedaM, FukuharaR, ShigenobuK, HokoishiK, MakiN, NebuA, KomoriK, TanabeH (2004) Dementia associated mental and behavioural disturbances in elderly people in the community: Findings from the first Nakayama study. J Neurol Neurosurg Psychiatry75, 146–148.
8.
ShinIS, CarterM, MastermanD, FairbanksL, CummingsJL (2005) Neuropsychiatric symptoms and quality of life in Alzheimer disease. Am J Geriatr Psychiatry13, 469–474.
9.
PoirierJ, DavignonJ, BouthillierD, KoganS, BertrandP, GauthierS (1993) Apolipoprotein E polymorphism and Alzheimer’s disease. Lancet342, 697–699.
10.
LiuCC, KanekiyoT, XuH, BuG (2013) Apolipoprotein E and Alzheimer disease: Risk, mechanisms and therapy. Nat Rev Neurol9, 106–118.
11.
van der LeeSJ, WoltersFJ, IkramMK, HofmanA, IkramMA, AminN, van DujinCM (2018) The effect of APOE and other common genetic variants on the onset of Alzheimer’s disease and dementia: A community-based cohort study. Lancet Neurol17, 434–444.
12.
PanzaF, FrisardiV, SeripaD, D'OnofrioG, SantamatoA, MasulloC, LogroscinoG, SolfrizziG, PilottoA (2012) Apolipoprotein E genotypes and neuropsychiatric symptoms and syndromes in late-onset Alzheimer’s disease. Ageing Res Rev11, 87–103.
13.
D’OnofrioG, PanzaF, SeripaD, SancarloD, ParisF, CascavillaL, UrbanoM, GravinaC, FontanaA, SolfrizziV, PellegriniF, PiottoA (2011) The APOE polymorphism in Alzheimer’s disease patients with neuropsychiatric symptoms and syndromes. Int J Geriatr Psychiatry26, 1062–1070.
14.
GedaYE, KnopmanDS, MrazekDA, JichaGA, SmithGE, NegashS, BoeveBF, IvnikRJ, PetersenRC, PankratzVS, RoccaWA (2006) Depression, apolipoprotein E genotype, and the incidence of mild cognitive impairment: A prospective cohort study. Arch Neurol63, 435–440.
15.
KimJ, FischerCE, SchweizerTA, MunozDG (2017) Gender and pathology-specific effect of Apolipoprotein E genotype on psychosis in Alzheimer’s disease. Curr Alzheimer Res14, 834–840.
16.
HymanBT, TrojanowskiJQ (1997) Consensus recommendations for the post-mortem diagnosis of Alzheimer disease from the National Institute of Aging and the Reagan Institute working group on diagnostic criteria for the neuropathological assessment of Alzheimer disease. J Neuropathol Exp Neurol56, 1095–1097.
17.
TekinS, MegaMS, MastermanDM, ChowT, GarakianJ, VintersHV, CummingsJL (2001) Orbitofrontal and anterior cingulate cortex neurofibrillary tangle burden is associated with agitation in Alzheimer disease. Ann Neurol49, 355–361.
18.
MarshallGA, FairbanksLA, TekinS, VintersHV, CummingsJL (2006) Neuropathologic correlates of apathy in Alzheimer's disease. Dement Geriatr Cogn Disord21, 144–147.
19.
FarberNB, RubinEH, NewcomerJW, KinscherfBA, MillerJP, MorrisJC, OlneyJW, McKeelDWJr (2000) Increased neocortical neurofibrillary tangle density in subjects with Alzheimer disease and psychosis. Arch Gen Psychiatry57, 1165–1173.
20.
FischerCE, QianW, SchweizerTA, MillikinCP, IsmailZ, SmithEE, LixLM, SheltonP, MunozDG (2016) Lewy bodies, vascular risk factors, and subcortical arteriosclerotic leukoencephalopathy, but not Alzheimer pathology, are associated with development of psychosis in Alzheimer’s disease. J Alzheimers Dis50, 283–295.
21.
TuMC, HuangWH, HsuYH, LoCP, DengJF, HuangCF (2017) Comparison of neuropsychiatric symptoms and diffusion tensor imaging correlates among patients with subcortical ischemic vascular disease and Alzheimer’s disease. BMC Neurol17, 144.
22.
WuMK, LuYT, HuangCW, LinPH, ChenNC, LuiCC, ChangWN, LeeCC, ChangYT, ChenSF, ChangCC (2015) Clinical significance of cerebrovascular biomarkers and white matter tract integrity in Alzheimer disease: Clinical correlations with neurobehavioral data in cross-sectional and after 18 months follow-ups. Medicine (Baltimore)94, e1192.
23.
HironoN, MoriE, YasudaM, ImamuraT, ShimomuraT, HashimotoM, TanimukaiS, KazuiH, YamashitaH (1999) Lack of effect of Apolipoprotein E E4 allele on neuropsychiatric manifestations in Alzheimer’s disease. J Neuropsychiatry Clin Neurosci11, 66–70.
24.
van der FlierWM, StaekenborgS, PijnenburgYA, GillissenF, RomkesR, KokA, BouwmanFH, ScheltensP (2007) Apolipoprotein E genotype influences presence and severity of delusions and aggressive behavior in Alzheimer disease. Dement Geriatr Cogn Dis23, 42–44.
25.
RobertsonJ, CurleyJ, KayeJ, QuinnJ, PfankuchT, RaberJ (2005) ApoE isoforms and measures of anxiety in probable AD patients and Apoe -/- mice. Neurobiol Aging26, 637–643.
26.
ChungEJ, BabulalGM, MonsellSE, CairnsNJ, RoeCM, MorrisJC (2015) Clinical features of Alzheimer disease with and without Lewy bodies. JAMA Neurol72, 789–796.
27.
WiderC, RossOA, NishiokaK, HeckmanMG, Vilariño-GuellC, Jasinka-MygaB, Erketin-TanerN, RademakersR, Graff-RadfordNR, MashDC, PapapetropoulusS, DuaraR, UchikadoH, WszolekZK, FarrerMJ, DicksonDW (2012) An evaluation of the impact MAPT, SNCA and APOE on the burden of Alzheimer and Lewy body pathology. J Neurol Neurosurg Psychiatry83, 424–429.
ShinoharaM, MurrayME, FrankRD, ShinoharaM, DeTureM, YamazakiY, TachibanaM, AtagiY, DavisMD, LiuCC, ZhaoN, PainterMM, PetersenRC, FryerJD, CrookJE, DicksonDW, BuG, KanekiyoT (2016) Impact of sex and APOE4 on cerebral amyloid angiopathy in Alzheimer’s disease. Acta Neuropathol132, 225–234.
30.
Vik-MoAO, BenczeJ, BallardC, HortobagyiT, AarslandD (2019) Advanced cerebral amyloid angiopathy and small vessel disease are associated with psychosis in Alzheimer’s disease. J Neurol Neurosurg Psychiatry90, 728–730.
31.
GleasonA, HayhowB, EmmanuelJ, GaillardF (2014) Cerebral amyloid angiopathy presenting with neuropsychiatric symptoms. Aust N Z J Psychiatry48, 779–780.
32.
JellingerKA, AttensJ (2008) Cerebral amyloid angiopathy in Lewy body disease. J Neural Transm115, 473–482.
33.
JellingerKA (2010) Prevalence and impact of cerebrovascular lesions in Alzheimer and Lewy body diseases. Neurodegener Dis7, 112–115.
